Prostate cancer
mCRPC: novel and emerging agents
Obiettivo della formazione: To gain insight in the new and emerging agents for mCRPC; for which patients are these treatments indicated and how do they fit in the sequence of mCRPC treatments commonly used in daily practice.
Specializzazione: Medical oncology, Clinical oncology, Urology
Pubblico target: CME (intermediate), Residents (senior)
Aggiornamento più recente: April 2023
Premessa:
mCRPC is a heterogeneous disease with diverse drivers of progression and mechanisms of therapeutic resistance. New therapeutic agents for mCRPC are (being) developed based on increasing knowledge about the biology of PCa and the availability of next-generation sequencing tools to identify genetic alterations.
Regulatory approval status of drugs for mCRPC discussed in this topic (indications limited to the mCRPC setting; status 4 April 2023)
